Pieris Pharmaceuticals, Inc. Stock News

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Pieris Pharmaceuticals, Inc. (NasdaqCM: PIRS) (the “Company”) and Palvella Therapeutics, Inc. Upon completion of the proposed transaction, Pieris shareholders are expected to own approximately 18% of the combine...

Poster presentations include data supporting QTORIN™ rapamycin 3.9% anhydrous gel as a potential targeted therapy for the treatment of microcystic lymphatic malformations and a review of the Phase 3 SELVA study Poster presentations include data supporting QTORIN™ rapamycin 3.9% anhydrous gel as a potential targeted therapy for the treatment of microcystic lymphatic malformations and a review of...

FDA Orphan Products Grants are based on scientific and technical merit as determined by rare disease and regulatory experts

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and Palvella Therapeutics, Inc. is fair to Pieris shareholders. Pre-merger Pieris shareholders are expected to own approximately 18% of the combined company. Halper Sadeh encourages Pieris shareholders to click here to learn more about thei...

NEW YORK, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK , Aug. 14, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Kellanova (NYSE: K)'s sale to Mars, Incorporated for $83.50 per share in cash. If you are a Kellanova shareholder, click here to learn more about y...

NEW YORK , July 24, 2024 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) and its board of directors concerning the proposed acquisition of the company by Palvella Therapeutics, Inc. Pieris Pharmaceuticals stockholders are expected to own approximately 18% of the combined company. The transaction is expected to c...

MILWAUKEE, July 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Pieris (Nasdaq: PIRS) for possible breaches of fiduciary duty and other violations of law in its transaction with Palvella. Click here to learn how to join our investigation https://www.ademilaw.com/case/pieris-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.